Stocksigma LogoStocksigma Logo

Aristo Bio-Tech Reports H1 Results Ending 30th Sep'26

Aristo Bio-Tech and Lifescience reported standalone revenue from operations of ₹19,824.17 lakh for the half-year ended 30th Sep'26, down 22.7% YoY from

Aristo Bio-Tech Reports H1 Results Ending 30th Sep'26

Aristo Bio-Tech & Lifescience Ltd · Outcome · 15 Nov 2026, 2:09 am

Aristo Bio-Tech Reports H1 Results Ending 30th Sep'26 Aristo Bio-Tech and Lifescience reported standalone revenue from operations of ₹19,824.17 lakh for the half-year ended 30th Sep'26, down 22.7% YoY from ₹25,645.31 lakh in the period ended 30th Sep'25. Net profit rose 17.6% YoY to ₹490.19 lakh from ₹416.96 lakh, supported by lower material costs of ₹17,787.33 lakh. Profit before tax stood at ₹659.84 lakh versus ₹554.44 lakh YoY. Basic and diluted EPS improved to ₹7.20 from ₹6.12 YoY. Net operating cash flow for the period stood at ₹241.51 lakh.

Original exchange filing (PDF)

More announcements from Aristo Bio-Tech & Lifescience Ltd

All Aristo Bio-Tech & Lifescience Ltd announcements